Rita Nanda
University of Chicago
H-index: 55
North America-United States
Top articles of Rita Nanda
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor … | Cancer Research | Erika Hamilton Rinath Jeselsohn Sara Hurvitz Dejan Juric Hyo Han | 2024/5/2 |
Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis | Telemedicine and e-Health | Jincong Q Freeman Arnaaz Khwaja Fangyuan Zhao Rita Nanda Olufunmilayo I Olopade | 2024/3/1 |
Abstract PO2-05-03: Costs associated with adverse events in patients receiving treatment for hormone receptor positive/human epidermal growth factor receptor-2 negative … | Cancer Research | Anju Shah Amy Sainski-Nguyen Kristin Moore MK Rehnquist Rita Nanda | 2024/5/2 |
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC) | Elena Michaels Nan Chen Rita Nanda | 2024/3/6 | |
Validation of the RSClin risk calculator in the National Cancer Data Base | Cancer | Augustin GL Vannier Asim Dhungana Fangyuan Zhao Nan Chen Sarah Shubeck | 2024/4/15 |
Abstract RF02-06: AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N)+ trastuzumab (H) alone or combined with avelumab (A)+/-utomilumab (U) in patients (pts) with … | Cancer Research | Adrienne Waks Ruichao Shi Meredith Regan Chau Dang Cesar Santa-Maria | 2024/5/2 |
Abstract A002: Serum levels of immune markers associated with pathological complete response (pCR) and immune-related adverse events (irAEs) in early-stage breast cancer … | Cancer Research | Silver Alkhafaji Denise M Wolf Amrita Basu Lamorna Brown-Swigart Rita Nanda | 2024/2/1 |
Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial—Efficacy and biomarker discovery | Clinical Cancer Research | Kathy S Albain Christina Yau Emanuel F Petricoin Denise M Wolf Julie E Lang | 2024/2/16 |
Abstract PO1-19-08: Phase I trial of pegylated liposomal doxorubicin chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer | Cancer Research | Sangeetha Reddy Joyce O'Shaughnessy Navid Sadeghi Samira Syed Cesar Santa-Maria | 2024/5/2 |
Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer | Jincong Q Freeman Jori B Sheade Fangyuan Zhao Olufunmilayo I Olopade Dezheng Huo | 2024/2/1 | |
Immune subtyping in the Response Predictive Subtypes (RPS) identifies a subset of triple negative (TN) early-stage breast cancer patients with a very low likelihood of response … | European Journal of Cancer | DM Wolf C Yau J Haan D Wehkamp A Witteveen | 2024/3/1 |
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study | Nature communications | Filipa Lynce Candace Mainor Renee N Donahue Xue Geng Greg Jones | 2024/3/27 |
Abstract PO1-14-12: Quantitative Biomarkers and 21-Gene Assay Results Predict Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive … | Cancer Research | Jincong Freeman Sarah Shubeck Nan Chen Rita Nanda Dezheng Huo | 2024/5/2 |
Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer | The Lancet Oncology | Nan Chen Rita Nanda | 2024/2/8 |
Immune subtyping identifies a subset of HR+ HER2-early-stage breast cancer patients with a very high likelihood of response to neoadjuvant immunotherapy (IO): Results from 5 IO … | Cancer Research | Denise M Wolf Christina Yau Lajos Pusztai Rita Nanda Jo Chien | 2024/3/22 |
Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER–positive/human … | Cancer Research | Sara Hurvitz Anne Schott Cynthia Ma Rita Nanda George Zahrah | 2024/5/2 |
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer. | Nan Chen Elena Michaels Poornima Saha Murtuza M Rampurwala Olwen Mary Hahn | 2023/6/1 | |
Racial differences in patterns of clinical trial discussion and participation among breast cancer patients at the University of Chicago. | Jincong Q Freeman Nan Chen Sudha Yarlagadda Fangyuan Zhao Dezheng Huo | 2023/6/1 | |
Abstract P6-05-19: Racial Disparities in the Quality of Life and Vaccination of Breast Cancer Survivors during COVID-19: A Longitudinal Study | Cancer Research | Fangyuan Zhao Brenda L Copley Sondra H Birch Rita Nanda Olufunmilayo I Olopade | 2023/3/1 |
Abstract P5-03-18: Co-occurring alterations in PALB2 germline carriers identified by liquid biopsy in patients with advanced breast cancer | Cancer Research | Nan Chen Rita Nanda Frederick M Howard Neelima Vidula Jennifer Yen | 2023/3/1 |
